SPHERA FUNDS MANAGEMENT LTD.

Position in TRVI — Trevi Therapeutics, Inc.

CIK 1496201 TEL AVIV, L3

Back to TRVI Full portfolio

Position in TRVI

as of Mar 31, 2026 · filed May 15, 2026 Compact

Position Value

$6,848,165

-$645,480 QoQ

Shares Held

574,029

-4.1% QoQ

Ownership

0.404%

of shares outstanding

% of Portfolio

1.19%

of 13F equity value

Holder Rank

—

not a current holder

Holding Since

Jun 2025

4 quarters on record

Voting authority Sole 100.ToString("F0")% Shared 0.ToString("F0")% None 0.ToString("F0")%

Common Shares in TRVI Over Time

Shares Held

Position Value (USD)

Derivatives in TRVI

reported options exposure · as of Sep 30, 2025

CallValue

$1,182,180

CallShares

129,200

PutValue

PutShares

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Mar 31, 2026

SPHERA FUNDS MANAGEMENT LTD. holds $325,221,568 across 61 Biotechnology names. TRVI ranks #14 (2.1% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	MLYS	Mineralys Therapeutics, Inc.	1,339,971	$36,299,814
2	BBIO	BridgeBio Pharma, Inc.	245,246	$18,211,967
3	RARE	Ultragenyx Pharmaceutical Inc.	809,333	$16,955,526
4	SNDX	Syndax Pharmaceuticals Inc	724,563	$16,925,791
5	COGT	Cogent Biosciences, Inc.	416,340	$16,024,926
6	FOLD	AMICUS THERAPEUTICS, INC.	603,377	$8,724,831
7	APLS	Apellis Pharmaceuticals, Inc.	214,914	$8,645,990
8	BMRN	Biomarin Pharmaceutical Inc	139,900	$7,902,951

All Filings in TRVI

Export CSV

5 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-03-31	$6,848,165	574,029	-4.1%	Shares	Defined	2026-05-15
2025-12-31	$7,493,645	598,534	+363.3%	Shares	Defined	2026-02-17
2025-09-30	$1,182,180	129,200	-79.9%	Call	Defined	2025-11-14
2025-09-30	$5,892,206	643,957	-19.5%	Shares	Defined	2025-11-14
2025-06-30	$4,375,764	799,957	—	Shares	Defined	2025-08-14
No filing history on record for this holder in this stock.